Dallas, TX -- (SBWIRE) -- 02/06/2015 -- The report "Amyloidosis – Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Amyloidosis. Amyloidosis is a rare but serious condition in which an abnormal protein builds up in tissues and organs. Two thirds of patients with amyloidosis are male and less than 5% of patients are under 40 years of age. The cause of primary amyloidosis is unknown and it can lead to conditions that include Carpal tunnel syndrome, Heart muscle damage, Kidney failure, Intestinal malabsorption, Liver swelling, Nerve problems, Nephrotic syndrome and Orthostatic hypotension.

The report also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects. Companies discussed in this Amyloidosis – Pipeline Review, H1 2015 report include Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics, Inc, Auven Therapeutics Management L.L.L.P, Bellus Health Inc., Bsim2, Celgene Corporation, GlaxoSmithKline plc, Immune System Therapeutics Ltd., Isis Pharmaceuticals, Inc., NeuroPhage Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., Pfizer Inc., ProteoTech, Inc., Prothena Corporation plc, SOM Innovation Biotech SL, Takeda Oncology.

Symptoms depend on the organs affected & it may includes irregular heartbeat, swollen tongue, fatigue, numbness of hands or feet, shortness of breath, skin changes, swallowing problems, swelling in the arms and legs, weak hand grip, weight loss, decreased urine output, diarrhea, hoarseness or changing voice, joint pain & weakness. Drug profiles discussed in this report include ALN-TTRsc, ALNTTR-01, Antisense Oligonucleotide for Transthyretin Amyloidosis, carfilzomib, eprodisate disodium, GSK-2315698, GSK-2398852, ISIS-TTRRx, IST-1097, ixazomib citrate, LUNAR-102, Monoclonal Antibody for Amyloidosis, Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy, NEOD-001, NPT-005, patisiran, pomalidomide, PTI-110, RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis, Small Molecule for AL Amyloidosis, Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy, Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy, tafamidis meglumine and tolcapone.

Order a Purchase copy of this report
http://www.rnrmarketresearch.com/contacts/purchase?rname=269548

(This is a premium report priced at US$2000 for a single user License.)

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Featured News & Press Releases

-Dec 15, 2014: Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis

-Dec 11, 2014: Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis

-Dec 11, 2014: Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis

-Dec 02, 2014: Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis

-Dec 01, 2014: Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis

-Nov 14, 2014: Alnylam Announces Positive Initial Phase 2 Data with Revusiran

-Nov 05, 2014: Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR Cardiac Amyloidosis

-Oct 14, 2014: Alnylam Presents Additional Data From Phase 1 Trial With ALN-TTRsc At 10th Annual Meeting of the Oligonucleotide Therapeutics Society

-Oct 13, 2014: Arcturus Therapeutics to Present Gene Knockdown Data in Non-Human Primates, Showing up to 94% Reduction in Gene Expression with a Single Low Dose

-Oct 13, 2014: Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)

Explore more reports on Therapeutics Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics